A case report on seronegative neuromyelitis optica spectrum disorder

G. Surya Kiran Reddy , J. Jeevaniya Anil, G Ramya Balaprabha * and T. Rama Rao

Department of Pharm D, CMR College of Pharmacy, Hyderabad, India.
 
Research Article
International Journal of Science and Research Archive, 2023, 10(02), 661–663.
Article DOI: 10.30574/ijsra.2023.10.2.1001
Publication history: 
Received on 23 October 2023; revised on 04 December 2023; accepted on 07 December 2023
 
Abstract: 
An inflammatory, demyelinating, autoimmune disease that primarily affects the central nervous system mainly targeting optic nerve and spinal cord is called neuromyelitis optica (NMO). The term NMOSD refers to a recently revised nomenclature that includes new diagnostic criteria, such as serum aquaporin-4 immunoglobulin G (AQP4-IgG) antibody serological testing.
One of the two common symptoms of NMOSD is optic neuritis or myelitis, which might appear as the initial symptom. And other symptoms include weakness, numbness, paralysis of limbs, nausea, vomiting, imbalance.
It is thought to be related to an autoimmune reaction in which the immune system unintentionally targets healthy cells, particularly targeting proteins in the central nervous system like aquaporin-4. Seronegative NMOSD is treated with methylprednisolone, plasma exchange therapy, and IV immunoglobulin-G therapy.
 
Keywords: 
Seronegative neuromyelitis optica spectrum disorder; Autoimmune disease; Serum Aquaporin-4 immunoglobulin G; Methylprednisolone; Optic neuritis; Optic myelitis
 
Full text article in PDF: 
 
Copyright information: 

Copyright © 2023 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0